Lysosomal Disorders 1
The Lysosomal Disorders 1 session will be discussing MPSI-VII, Oligosaccharidoses, Mucolipidoses.
Commercial Supporter
This educational activity is supported by an educational grant from Ultragenyx.
Learning Objectives
At the conclusion of this session, participants should be able to:
- Enumerate the manifestations of lysosomal storage diseases on different organ systems
- Understand the different approaches to treating lysosomal storage diseases
- Appreciate the known reasons for variability in mucopolysaccharidoses, Pompe, Gaucher and Fabry disease
Guest Faculty
William Wilcox, MD, PhD
Emory University
Disclosures
William Wilcox, MD, PhD, speaker for this activity, is on the advisory board for Sanofi-Genzyme, Chiesi and Takeda, is a principle investigator on contracted clinical research for Amicus Therapeutics, BioMarin, Protalix, Chiesi, Takeda, Alexion/AstraZeneca, 4D Molecular Therapeutics, Sangamo, Astellas, Denali, Cyclo Therapeutics and Pfizer, is a consultant for Spark Therapeutics/Roche and UniQure, and has received a research grant from Amicus Therapeutics and Takeda.
Planners, faculty, and others in control of content (either individually or as a group) have no relevant financial relationships with ineligible companies.
All of the relevant financial relationships listed have been mitigated.
Medical
Children’s Hospital Colorado is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Children’s Hospital Colorado designates this Live activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Others
A general certificate of attendance will be available after the completion of the online evaluation. Claim only credit commensurate of your conference attendance.
Available Credit
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Attendance